Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Silexion Therapeutics (SLXN).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Naz Rahman has given his Buy rating due to a combination of factors that highlight Silexion Therapeutics’ promising future. The company is advancing its SIL-204 therapy, which targets pancreatic cancer, into Phase 2b/3 studies, with plans to expand its use to treat both locally advanced and metastatic pancreatic cancers. This expansion significantly increases the market potential for SIL-204, as it will address a broader patient population.
Furthermore, Silexion has demonstrated positive pre-clinical data showing the anti-tumor activity of SIL-204, and previous formulations have shown promising results in improving overall survival and reducing the risk of death in clinical trials. The company is also financially positioned to support its operations into 2026, with sufficient capital and access to an equity line of credit. These factors, combined with a strategic plan to initiate human studies and regulatory submissions, underpin the optimistic outlook and justify the Buy rating.